191 related articles for article (PubMed ID: 27069184)
21. IMRT-SIB with concurrent and neo-adjuvant platinum-based chemotherapy for locally advanced head and neck squamous cell cancer: analysis of clinical outcomes in a retrospective series of a single institution.
Mazzeo E; Antognoni P; Parmiggiani M; D'Ambrosio C; De Marco G; Marra L; Gottardi G; Bertoni F
Tumori; 2014; 100(6):652-9. PubMed ID: 25688499
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma.
Clavel S; Nguyen DH; Fortin B; Després P; Khaouam N; Donath D; Soulières D; Guertin L; Nguyen-Tan PF
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):582-9. PubMed ID: 21277695
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
[TBL] [Abstract][Full Text] [Related]
24. Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Lohynská R; Nýdlová A; Drbohlavová T; Mazaná E; Jirkovská M; Veselský T; Malinová B; Stankušová H
Klin Onkol; 2020; 33(4):288-294. PubMed ID: 32894958
[TBL] [Abstract][Full Text] [Related]
25. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach.
Leclerc M; Maingon P; Hamoir M; Dalban C; Calais G; Nuyts S; Serre A; Grégoire V
Radiother Oncol; 2013 Mar; 106(3):333-40. PubMed ID: 23541643
[TBL] [Abstract][Full Text] [Related]
26. Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?
Zilli T; Schick U; Ozsahin M; Gervaz P; Roth AD; Allal AS
Radiother Oncol; 2012 Jan; 102(1):62-7. PubMed ID: 21993403
[TBL] [Abstract][Full Text] [Related]
27. High-tailored Anal Canal Radiotherapy (HIT-ART): Outcomes of a 10-Year Single Center Clinical Experience.
Manfrida S; Fionda B; Mariani S; Luca V; Bertolini R; Barbaro B; Chiloiro G; Frascino V; Tagliaferri L; Gambacorta MA
In Vivo; 2024; 38(3):1306-1315. PubMed ID: 38688632
[TBL] [Abstract][Full Text] [Related]
28. Twenty-five-year experience with radical chemoradiation for anal cancer.
Tomaszewski JM; Link E; Leong T; Heriot A; Vazquez M; Chander S; Chu J; Foo M; Lee MT; Lynch CA; Mackay J; Michael M; Tran P; Ngan SY
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):552-8. PubMed ID: 22019078
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
[TBL] [Abstract][Full Text] [Related]
31. Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival.
Weber HE; Dröge LH; Hennies S; Herrmann MK; Gaedcke J; Wolff HA
Strahlenther Onkol; 2015 Nov; 191(11):827-34. PubMed ID: 26050046
[TBL] [Abstract][Full Text] [Related]
32. Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Nilsson MP; Johnsson A; Scherman J
Radiat Oncol; 2021 Aug; 16(1):152. PubMed ID: 34399812
[TBL] [Abstract][Full Text] [Related]
33. Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.
Untiedt S; Rolf D; Scobioala S; Wolters H; Elsayad K; Oertel M; Kittel C; Pascher A; Rijcken E; Ullerich H; Glasbrenner B; Eich HT
Strahlenther Onkol; 2023 Aug; 199(8):749-760. PubMed ID: 36862155
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
[TBL] [Abstract][Full Text] [Related]
35. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
Passoni P; Reni M; Cattaneo GM; Slim N; Cereda S; Balzano G; Castoldi R; Longobardi B; Bettinardi V; Gianolli L; Gusmini S; Staudacher C; Calandrino R; Di Muzio N
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1000-6. PubMed ID: 24267968
[TBL] [Abstract][Full Text] [Related]
36. Could concomitant radio-chemotherapy improve the outcomes of early-stage node negative anal canal cancer patients? A retrospective analysis of 122 patients.
De Bari B; Lestrade L; Pommier P; Maddalo M; Buglione M; Magrini SM; Carrie C
Cancer Invest; 2015 Apr; 33(4):114-20. PubMed ID: 25674700
[TBL] [Abstract][Full Text] [Related]
37. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
[TBL] [Abstract][Full Text] [Related]
38. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
39. Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients.
De Bari B; Lestrade L; Franzetti-Pellanda A; Jumeau R; Biggiogero M; Kountouri M; Matzinger O; Miralbell R; Bourhis J; Ozsahin M; Zilli T
J Cancer Res Clin Oncol; 2018 Apr; 144(4):781-789. PubMed ID: 29441419
[TBL] [Abstract][Full Text] [Related]
40. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.
Folkert MR; Shih KK; Abu-Rustum NR; Jewell E; Kollmeier MA; Makker V; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Feb; 128(2):288-93. PubMed ID: 23159818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
